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doi:10.1016/j.ejvs.2009.12.003Abstract Objective: This study aims to evaluate mortality across ankleebrachial index (ABI)
values and to assess the association between elevated ABI, peripheral arterial disease (PAD)
and mortality.
Design: This is a retrospective clinical study.
Material and methods: A total of 2159 patients referred with a suspicion of PAD had their ABI
and toe brachial index (TBI) measured by photoplethysmography. ABI 1.3 was considered
falsely elevated while TBI <0.60 was the diagnostic criterion for PAD among the subjects.
The cohort was followed up for total and cardiovascular mortality until 30 June 2008, by record
linkage with the National Causes-of-Death Register.
Results: The average follow-up time was 39 months. A total of 576 (26.7%) patients died during
the follow-up. Mortality was highest in the elevated ABI group (35.7% for elevated ABI; 30.1%
for low ABI and 16.0% for normal ABI, p < 0.001). There was a greater than twofold risk of
total, and an increased but statistically non-significant risk of, cardiovascular mortality among
patients with elevated ABI. Similar risk ratios were noted for the low ABI (0.9) group. More
pronounced associations were observed at both ends of the scale when ABI was divided into
sub-categories. The overall survival was significantly worse for the elevated ABI group than
for both the normal and the low-ABI group (p < 0.01 and p Z 0.013, respectively). PAD was
found to be independently associated with both total and cardiovascular mortality among
those with elevated ABI (odds ratio (OR): 2.21; 95% confidence interval (CI): 1.01e4.85 and
OR: 4.90; 95% CI: 1.50e16.04, respectively).
Conclusions: The association between elevated ABI and poor survival is similar to that of lowABI.
PAD appears to be an independent risk factor for mortality among patients with elevated ABI.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.3 31165049; fax: þ358 3 31164342.
n@pshp.fi (V. Suominen).
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Mortality Among Patients with Elevated ABI 317The prevalence of peripheral arterial disease (PAD)
increases with age and affects 10e25% of the population
older than 55 years of age.1,2 The disorder carries an
elevated risk of cardiovascular disease (CVD) and prema-
ture death but remains an under-diagnosed problem in the
primary care setting.3,4 The determination of the anklee
brachial pressure index (ABI) using Doppler techniques is an
established non-invasive means of diagnosing PAD. An ABI
0.9 serves as the diagnostic tool most commonly used to
define PAD.5 Ankle pressures and, consequently, ABI can be
falsely elevated due to medial arterial calcification (MAC),
which complicates clinical decision making and PAD diag-
nosis. In such cases, as MAC does not usually affect toe
vessels, the measurement of toe pressures and toe brachial
index (TBI) is recommended.6e8 Unfortunately, this method
is rarely applied in routine clinical practice and is often
available only in specialised vascular units.
The association between low ABI and increased total and
cardiovascular mortality is well established.4,9 According to
the available literature, the risk increases as the ABI
diminishes and is approximately four- to fivefold among
patients with an ABI <0.6.9,10 At the same time, the clinical
significance of elevated ABI is not as clear as that of low
ABI, and the problem has attracted little interest until
recently. Based on the results of two epidemiological
studies, elevated ABI is increasingly recognised as being
associated with high all-cause and cardiovascular mortality
similar to low ABI.11,12 Therefore, the association between
ABI and mortality appears to be U shaped across the ABI
spectrum. Furthermore, two recently published papers
have demonstrated an increased prevalence of PAD among
patients with elevated ABI.13,14 To our knowledge, no
previous studies have assessed the possible role of PAD in
increased mortality associated with elevated ABI.
The present objectives were (1) to evaluate mortality
across the full spectrum of ABI values among patients
admitted to the university hospital vascular outpatient
clinic for evaluation purposes and (2) to assess the associ-
ation between elevated ABI, PAD and mortality.
Material and Methods
Study population
This is a retrospective analysis of consecutive patients
referred to the vascular outpatient clinic at Tampere
University Hospital (TAUH), Finland, between April 2002
and December 2006. Patients with suspected lower
extremity arterial insufficiency were included in the study.
TAUH serves a region with roughly 470,000 inhabitants, and
all vascular surgical consultations, diagnostics and proce-
dures are carried out exclusively at TAUH. Patients are
referred to the outpatient clinic not only from the munic-
ipal health centres but also from regional cardiac, renal and
other units located within the TAUH district. Every patient
visit to the hospital is recorded in the central register with
the diagnosis and reason for attendance. An attempt to
measure ABI and TBI was made of all new admissions
(N Z 2654) during the study period. The pressure
measurements were unsuccessful in 62 cases (2.3%). Cases
with successful measurements and with no prior lowerextremity vascular procedures (N Z 2159; 81.3%) were
subjected to further analysis. The need for ethical approval
was waived based on the retrospective nature of the study.
Risk factors for PAD and other co-morbid diseases
Data from the patients’ files were collected systematically
by one examiner (VS). The following risk factors, identified
from case records, were included in the analysis: age, sex,
diabetes mellitus, hyperlipidaemia, hypertension, smoking
within 5 years, CVDs other than PAD (coronary heart disease
(CHD), cerebrovascular disease, etc.), respiratory disease
and chronic renal failure in addition to stored images. The
diagnosis for each disease was considered positive if it had
been previously established at TAUH or mentioned in the
referral, or if the patient was on appropriate medication.
No distinction was made between chronic renal failure and
end-stage renal disease (ESRD).
Measurement of ABI/TBI and definitions
ABI and TBI were measured using the Nicolet VasoGuard
(Nicolet Vascular Inc., Madison, WI, USA), a device that
allows simultaneous systolic blood pressure measurements
from upper and lower extremities by means of photo-
plethysmography. Measurements were carried out by
trained vascular nurses following standard protocol (supine
position, room temperature, after a rest period of 10 min).
Photoplethysmographic probes were attached to the tips of
the big toes, and appropriately sized blood pressure cuffs
were placed on the arms and legs above the ankle or at the
base of the big toes. Because of the known association
between subclavian stenosis and PAD,15 the higher of the
two simultaneously measured brachial systolic blood pres-
sure values was used in the analysis. As a rule, values
obtained from single ABI or TBI measurements of good
quality were used. ABI  0.9 was considered low, ABI > 0.9
or <1.3 was considered normal and ABI  1.3 was consid-
ered falsely elevated. Patients with an ABI  0.9 and/or
TBI < 0.6 in either leg were regarded as presenting with
PAD. Patients with an ABI  1.3 in both legs or in one leg, in
latter case of which the other side had to be normal, were
categorised as belonging to the elevated-ABI group. For
additional analysis, the ABI was further categorised into six
ranges according to the lowest leg ABI: 0.5;
0.5 < ABI  0.7; 0.7 < ABI  0.9; 0.9 < ABI < 1.3 (refer-
ence); 1.3  ABI  1.5; >1.5.Mortality
Two end points, total and cardiovascular mortality, were
analysed. Themortality follow-up data were available for up
to 39 months (range: 0e76 months) until 30 June 2008.
Deaths were ascertained by record linkage of the study data
to the National Causes-of-Death Register, on the basis of the
personal identification code unique to every resident in
Finland. Cardiovascular death was defined as death due to
CHD, myocardial infarction, sudden cardiac death, stroke or
PAD using the appropriate International Classification of
Diseases 10 (ICD-10) codes (I20e25, I46.1, I46.2, I63eI65, I70).
Table 1 Baseline characteristics of participants depending on ABI level (N Z 2159).
Measure ABI  0.9
N Z 1381 (%)
0.9 < ABI < 1.3
N Z 593 (%)
ABI  1.3
N Z 185 (%)
p-value
Diabetes mellitus 468 (34) 178 (30) 90 (49) <0.001
Hyperlipidaemia 398 (29) 164 (28) 39 (21) 0.087
Hypertension 760 (55) 267 (45) 87 (47) <0.001
Smoking 441 (32) 104 (18) 19 (10) <0.001
CHD 485 (35) 165 (28) 74 (40) 0.001
Cerebrovascular disease 151 (11) 51 (9) 17 (9) 0.262
Respiratory disease 172 (13) 41 (7) 22 (12) 0.001
Renal failure 79 (6) 32 (5) 27 (15) <0.001
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A digital subtraction angiography (DSA) was performed for 82
(44%) patients with elevated ABI (N Z 185) after the initial
consultation. The angiography images were reviewed for the
presence of PAD, defined as >50% narrowing of the arterial
lumen in any arterial segment of the lower extremities.
Statistical analysis
Statistical Package for the Social Sciences (SPSS) version
17.0 for Windows was used for statistical analysis (SPSS, v.
17, Chicago, IL, USA). For discrete variables, analyses were
made with the aid of cross-tabulations combined with c2
tests, and comparisons of means between the two groups
were carried out with the t-test for independent samples.
Logistic regression analysis was used to evaluate the inde-
pendent association between ABI values and total and
cardiovascular mortality by entering variables such as age,
sex and classical PAD risk factors into the model. Survival
analysis with log-rank test was used to examine mortality




There were 1261 (58.4%) men and 898 (41.6%) women
available for the analysis. The mean age in the cohort was
69.7  11.8 years. The PAD patients were almost 5 years
older than those with normal ABI, while those with elevated
ABI formed the intermediate group (p < 0.001). Low ABI
was detected in 1381 (64.0%) patients; 593 (27.4%) had
normal and 185 (8.6%) had elevated ABI. Table 1 shows the
baseline characteristics of the ABI categories. In general,
less favourable profiles were observed among those with
high or low ABI when compared with those with normal ABI.
Predictably, diabetes and chronic renal failure were more
common in patients with elevated ABI.
Whereas themain reason for referral among thosewith low
and normal ABI was intermittent claudication (60.0% and
49.7%, respectively), the primary cause for those with
elevated ABI was critical limb ischaemia (45.9%). Interest-
ingly, approximatelyone-quarter of those,whoeaccording to
our definitions e did not have PAD (NZ 666), presented with
symptoms of critical ischaemia, predominantlywith rest pain.Mortality
A total of 576 (26.7%) patients died during the follow-up,
a cardiovascular event being the most common cause of
death (N Z 298; 51.7%) (Table 2). The highest mortality
rate was noted in the elevated ABI group (35.7% for
elevated ABI; 30.1% for low ABI and 16.0% for normal ABI,
p < 0.001). According to the logistic regression model,
there was a greater than twofold risk of total mortality
among those with elevated ABI and an increased, but
statistically non-significant, risk of cardiovascular mortality
(Table 3). As demonstrated in Table 3, the risk ratios were
quite similar for the low-ABI group. The associations were
more pronounced at the highest and lowest end of the
scale, when the patients were divided into smaller ABI
subgroups (Table 3). The cumulative survival, as illustrated
in Fig. 1, was significantly worse for the elevated ABI group
than for both the normal and the low-ABI groups (p < 0.01
and p Z 0.013, respectively).
Elevated ABI, PAD and mortality
According to the TBI measurement, 112 (60.5%) of the
elevated ABI patients had PAD. The diagnosis was further
confirmed in all of the 82 patients who underwent angiog-
raphy. Of the 66 patients in the elevated ABI group who
died, 51 (77.3%) had PAD. To assess the factors that were
related to mortality, multivariate analysis (variables added
to the analysis included: age, sex, diabetes, hyper-
lipidaemia, hypertension, smoking, CHD, cerebrovascular
disease, respiratory disease and chronic renal failure) was
performed. PAD was found to be the most important, and
only, risk factor for both total and cardiovascular mortality
(OR: 2.21; 95% CI: 1.01e4.85 and OR: 4.90; 95% CI: 1.50e
16.04, respectively). Fig. 2 shows the overall survival of
patients with elevated ABI, depending on the presence of
PAD (p Z 0.002).
Discussion
According to our findings, elevated ABI is associated with
total and cardiovascular mortality similar to low ABI.
Therefore, our results for patients referred to the vascular
outpatient clinic are consistent with the results reported
earlier.11,12 Our findings further suggest that those with PAD
in the elevated ABI group have a significantly worse overall
survival rate and that PAD is a strong independent risk
Table 2 Causes of death during the follow-up (N Z 576).
Cause of death ABI  0.9
N Z 415 (%)
0.9 < ABI < 1.3
N Z 95 (%)
ABI  1.3
N Z 66 (%)
p-value
Infectious diseases 1 (0.2) 1 (1.1) 1 (1.5) 0.300
Neoplasms 79 (19.0) 11 (11.5) 6 (9.1) 0.077
Endocrine and metabolic diseases 8 (1.9) 4 (4.2) 4 (6.1) 0.107
Mental and behavioural disorders 6 (1.4) 0 (0) 1 (1.5) 0.496
Diseases of the nervous system 17 (4.1) 4 (4.2) 0 (0) 0.244
Cardiovascular diseasesa 222 (53.6) 47 (49.5) 30 (45.5) 0.445
Non-ischemic circulatory diseases 29 (7.0) 10 (10.5) 10 (15.2) 0.065
Diseases of the respiratory system 14 (3.4) 5 (5.3) 7 (10.6) 0.029
Diseases of the digestive system 15 (3.6) 5 (5.3) 3 (4.5) 0.738
Diseases of the musculoskeletal system 1 (0.2) 1 (1.1) 1 (1.5) 0.300
Diseases of the genitourinary system 6 (1.4) 2 (2.1) 1 (1.5) 0.896
Trauma 16 (3.9) 4 (4.2) 1 (1.5) 0.609
Non-specified 1 (0.2) 1 (1.1) 1 (1.5) 0.300
a Cardiovascular death was defined as death due to coronary heart disease, myocardial infarction, sudden cardiac death, stroke or
peripheral arterial disease, using appropriate ICD-10 codes (I20-25, I46.1, I46.2, I63-I65, I70).
Mortality Among Patients with Elevated ABI 319factor for total and cardiovascular mortality. Consequently,
PAD, or universal atherosclerosis, may well be the under-
lying cause of death among this group of patients.
PAD, defined as an ABI  0.9, has been associated with
increased total and cardiovascular mortality as well as CVD
morbidity in multiple populations, including both clinical
and community settings.4,9,10,16 The risk of total and
cardiovascular mortality among those with an ABI  0.9 is
between 1.5 and 1.8 compared with those with normal ABI;
the annual overall major cardiovascular event rate for PAD
patients is approximately 5e7%.5,17,18 Moreover, patients
with more severe disease, as measured by the ABI, are at
higher risk for CVD and total mortality. For example,
patients with critical limb ischaemia, usually accompanied
with very low ABI, are at an approximately 20% risk of dying
during the first year after presentation.5
Traditionally, elevated ABI values have been connected
with MAC, a common condition in patients with diabetes
and chronic renal disease and which is associated with
increased mortality.19e21 Consequently, elevated ABI has
been considered of little importance in the process of
diagnosing PAD. Leskinen and co-authors have even sug-
gested that MAC is an entity of its own, because only 25% ofTable 3 Odds ratios (95% CI) of total and cardiovascular morta
Measure ABI Total mortality
Crude Adjusteda
0.9 2.25 (1.76e2.89) 1.75 (1.34e
0.9 < ABI < 1.3 reference
1.3 2.91 (2.00e4.23) 2.25 (1.51e
0.5 3.25 (2.46e4.29) 2.38 (1.75e
0.5 < ABI  0.7 1.86 (1.39e2.48) 1.50 (1.10e
0.7 < ABI  0.9 1.41 (1.02e1.95) 1.23 (0.88e
0.9 < ABI < 1.3 reference
1.3  ABI  1.5 3.11 (1.81e5.35) 2.34 (1.31e
>1.50 5.27 (3.08e9.02) 3.43 (1.94e
a Variables that were added to the analysis included: age, sex, d
disease, cerebrovascular disease, respiratory disease, chronic renal fthe patients with MAC in their study had PAD as assessed by
TBI.21 In addition to MAC, ankle pressures can also become
falsely elevated due to the use of an excessively narrow
cuff. In this case, the problem can usually be avoided by
using cuffs that are at least 120% of the diameter of the
measuring site.6 If appropriately sized cuffs are used but
ABI still remains high, the measurement of TBI is recom-
mended to diagnose possible PAD.6e8 In the current study,
we used the American College of Cardiology and the
American Heart Association (ACC/AHA) recommendations
for elevated (non-compressible vessel) ABI, that is, 1.3,
although higher values (>1.4) have also been
proposed.5,12,22 For TBI, values <0.6 have been recom-
mended and used as a threshold for PAD.5,21 These
threshold values and the methods to measure ABI and TBI
can naturally be criticised. For example, the device used to
measure ABI and TBI in the current study is in clinical use
worldwide, but we found no studies on testeretest repro-
ducibility or validity for this particular equipment. This may
partly explain why 28% of those with low ABI did not have
TBI < 0.6 and that at the same time 27% of those with
normal ABI had PAD according to the TBI measurements.
The latter finding may be due to a high prevalence oflity across the ABI spectrum. Logistic regression model.
Cardiovascular mortality
Crude A djusteda
2.28) 2.21 (1.60e3.08) 1.66 (1.17e2.35)
reference
3.35) 2.25 (1.38e3.68) 1.64 (0.97e2.75)
3.23) 3.27 (2.28e4.68) 2.28 (1.54e3.37)
2.04) 1.74 (1.18e2.58) 1.36 (0.99e2.05)
1.73) 1.61 (1.06e2.47) 1.38 (0.88e2.14)
reference
4.19) 2.14 (1.02e4.40) 1.40 (0.65e3.04)
6.07) 4.74 (2.55e8.80) 3.05 (1.58e5.86)
iabetes, hyperlipidemia, hypertension, smoking, coronary heart
ailure.
Figure 1 Cumulative survival according to ABI category. KaplaneMeier survival analysis.
320 V. Suominen et al.diabetes and chronic renal failure (>40%) in this subgroup,
thus probably resulting in a somewhat falsely elevated ABI
among these patients.
During the past few years, there has been an increasing
body of evidence suggesting that elevated ABI is indepen-
dently associated with mortality, similarly to low
ABI.11,12,23 In the Strong Heart Study, a baseline ABI > 1.4
was associated with an approximately twofold increase in
both total and cardiovascular mortality compared to
a normal ABI (0.90e1.40).11 This finding was later sup-
ported by the results of the Cardiovascular Health Study,
thus confirming the U-shaped association between ABI and
mortality risk.12 Furthermore, there is evidence that both
low and high ABI carry the same risk of non-fatal cardio-
vascular events.24 The study by Ono and colleagues is
among the first clinical studies to link elevated ABI to higher
mortality.23 In their study on 1010 Japanese haemodialysis
patients, the authors found that those with an ABI < 1.1 or
>1.3 were at a higher risk of cardiovascular mortality than
those with an ABI between 1.1 and 1.3. However, not all
investigators share the opinion of a non-linear association
between ABI and mortality. The Atherosclerosis Risk in
Communities study (ARIC), for example, reported similar
CVD event rates in the elevated ABI (>1.3) and normal ABI
groups.25 The ARIC study population consisted of middle-
aged, comparatively healthy individuals with a relative low
prevalence of PAD risk factors. It was, therefore, correctly
noted that an elevated ABI value should not be consideredFigure 2 Time to death in the elevated-ABI group depending o
survival analysis.a definitive marker of increased CVD risk in low-risk
populations.25,26
All aforementioned studies operated only on ABI values.
Consequently, as TBI measurements were not performed or
angiograms reviewed, the authors were not able to specu-
late on the possible role of PAD in the association between
elevated ABI and mortality. Available data, albeit still
limited, suggest that elevated ABI is closely associated with
PAD, especially in high-risk populations. In their study in
diabetic subjects, Brooks and co-authors found that half of
the patients with elevated ABI (>1.3) had PAD.27 The value
of this information can be questioned, as only 16 patients
had elevated ABI, and a very low TBI threshold value
(0.54) was used. Another study with over 500 participants
demonstrated that low and high ABI values were similarly
(approximately 85%) associated with PAD as assessed by
a TBI below 0.7 and/or posterior tibial artery peak-flow
velocity below 10 cm s1.14 The authors further concluded
that diabetes is the dominant risk factor for high ABI
(1.4). Our earlier study among patients referred to
a vascular surgery unit for PAD diagnosis showed similar
findings, as 62% of those with an elevated ABI (>1.3) had
PAD (TBI < 0.6 and/or positive angiography findings).13
Finally, Wang and colleagues reported a higher prevalence
of intermittent claudication and atypical exertional leg
symptoms in patients with high ABI (>1.4) than those with
normal ABI values (1.1e1.4), suggesting a higher prevalence
of PAD among those with elevated ABI.28n the presence of PAD (defined as TBI < 0.6). KaplaneMeier
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information about the relationship between elevated ABI,
PAD and mortality. According to the results, PAD is inde-
pendently associated with both total and cardiovascular
mortality among those with high ABI. We believe that this
finding can explain the U-shaped association between ABI
and mortality. It also supports our belief that high ABI is
actually an equivalent to a low ABI. More studies are
needed to establish a solid threshold value, similar to the
0.9 for low ABI, in order to make a firm PAD diagnosis.
Interestingly, diabetes and chronic renal failure were not
significantly associated with mortality in the elevated ABI
group. The relatively small number of participants in the
elevated ABI group may partly explain this finding. This is
further supported by the finding that both diseases served
as an independent risk factor for mortality when evaluated
together with the whole study population. It should be
emphasised that the material in our study comprised
selected patients referred to a vascular surgical unit due to
lower extremity symptoms. This may affect any general-
isation, especially in terms of the general population. At
the same time, colleagues may find the current information
useful when evaluating patients and planning risk-factor
modification among those with suspected PAD.
There are several limitations to our study. As this is an
extension of our previous cross-sectional study, the same
limitations apply here, and they are reported elsewhere.14
In brief, the main drawback is the retrospective design,
involving possible data issues associated with the use of
hospital discharge histories and patient case records.
Furthermore, the number of patients with elevated ABI was
relatively small (N Z 185; 8.6%), which may limit the
statistical validity of our findings. By contrast, the Causes-
of-Death Register maintained by Statistics Finland contains
data from death certificates completed either by physicians
who treated the patients, or, in case of unclear or unnat-
ural deaths, by the physician who performed the autopsy.
The register includes all deaths of the citizens and
permanent residents of Finland. As it is possible to ascer-
tain deaths on the basis of the unique personal identifica-
tion code, our data can be considered reliable in this
respect. Another potential issue is the relatively short
duration of the follow-up. This could have an impact on the
results and the current material should therefore be
revisited in the years to come.
Conclusions
This paper confirms the U-shaped mortality previously
associated with ABI. Furthermore, and perhaps more
importantly, our study is among the first to demonstrate
that PAD serves as an independent and strong risk factor for
mortality among patients with elevated ABI. However,
more studies are needed to confirm our findings. For the
time being, a high-risk patient with an elevated ABI should
be treated as an equivalent to a PAD patient, with a clas-
sical ABI criterion, unless PAD can be ruled out.
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